We use cookies to analyze user behavior in order to constantly improve the website for you. View our Privacy Policy and Terms of Use.
May 05, 2026 10:08 AM EDT | Source: Adia Nutrition Inc.
Winter Park, Florida–(Newsfile Corp. – May 5, 2026) – Adia Nutrition, Inc. (OTCQB: ADIA), a publicly traded company based in Winter Park, Florida, dedicated to advancing regenerative therapies for chronic diseases, today announced that its pivotal clinical study on kidney disease has received Institutional Review Board (IRB) approval and has been successfully submitted to ClinicalTrials.gov.
Adia Nutrition Announces IRB Approval and ClinicalTrials.gov Submission for Groundbreaking Stem Cell Study in Chronic Kidney Disease (CKD)
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/295970_ckdstudy.jpg
This milestone marks an important step in Adia Nutrition’s ongoing research into new approaches for studying kidney disease. The approved study will focus on evaluating the safety of the company’s proprietary AdiaVita stem cell-based approach, which uses stem cells and exosomes derived from umbilical cord blood, in people with moderate to advanced chronic kidney disease (CKD). In addition to safety, the study will track changes in commonly used kidney function and inflammation markers over time to better understand how patients respond during the study period.
“IRB approval and our submission to ClinicalTrials.gov are important milestones that confirm this study meets established ethical and regulatory standards,” said Larry Powalisz, CEO of Adia Nutrition. “Reaching this stage allows us to move forward with participant recruitment and begin the structured process of collecting clinical data. We’re enthusiastic about advancing this research and gaining a clearer scientific understanding of our stem cell and exosome-based approach in individuals with chronic kidney disease.”
Key details of the upcoming study include:
Recruitment for the study is expected to commence immediately upon acceptance on ClinicalTrials.gov. Eligible participants and healthcare providers interested in the trial are encouraged to visit www.adiamed.com or monitor ClinicalTrials.gov for updates.
This advancement underscores Adia Nutrition’s commitment to rigorous, science-driven innovation in the regenerative medicine sector and its focus on addressing large unmet medical needs through cutting-edge stem cell interventions.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. (OTCQB: ADIA), based in Winter Park, Florida, is a publicly traded company advancing healthcare through innovation. The company specializes in sales of stem cell and regenerative products, such as AdiaVita and AdiaLink, through its lab division, Adia Labs LLC, which is expanding to include insurance-billable wound care products. Adia is also growing nationwide with Adia Med clinics, specializing in orthopedic, pain management, and wound repair. Adia Med clinics also offer specialized regenerative treatments like stem cell therapies and platelet-rich plasma (PRP), advanced treatments including therapeutic plasma exchange (TPE) and autologous hematopoietic stem cell transplantation (aHSCT), and wound repair services.
Revenue is generated through service fees, product sales, equity stakes, and billing insurance for healthcare treatments. Additionally, Adia Nutrition Inc. invests in aligned businesses such as Cement Factory LLC, a nutrition and supplement company with shared values and a focus on health and wellness. Through bold partnerships with top-tier medical entities and unwavering dedication to standardized, FDA-approved lab protocols, Adia Nutrition Inc. is revolutionizing healthcare, igniting a nationwide movement to empower communities with groundbreaking regenerative solutions and vibrant, holistic wellness.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company’s current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company’s business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/295970
Source: Adia Nutrition Inc.
Analyst, journalist, or company stakeholder? Sign up to receive news releases by email for Adia Nutrition Inc. or all companies in the Health, Healthcare and Hospitals industry.
Adia Nutrition Announces IRB Approval and ClinicalTrials.gov Submission for Groundbreaking Stem Cell Study in Chronic Kidney Disease (CKD)
2026-05-05 10:08 AM EDT
Adia Nutrition Announces Three Pivotal Clinical Studies Receive Major IRB Milestone – Final Approval Now Clearly in Sight
2026-04-28 8:30 AM EDT
Adia Nutrition, Inc. Looking to Acquire Larger Property to Expand Flagship Clinic in Winter Park, Reports Strong Operational Momentum in Q1 2026 and Provides Optimistic Outlook for Remainder of the Year
2026-04-22 8:00 AM EDT
Dec 18, 2025
In 2025, more than 39,000 press releases distributed through Newsfile offer a clear lens into how public companies are communicating with the market. At this scale, individual announcements fade into the background, and what emerges instead are patterns . The language companies choose reveals how industries are evolving, where credibility is being built, and what investors are being asked to trust. Last year, this analysis focused on identifying the most common keywords by industry. This…
Economy, Business and Finance
Health
Hospital and Clinic
Health
Healthcare and Hospitals
Send us a message and a member of our TMX Newsfile team will contact you to discuss your needs.
TMX Group Limited and its affiliates do not endorse or recommend any companies or businesses (including but not limited to investment advisors/firms), or securities issued by any companies identified on, or linked through, this site. Please seek professional advice to evaluate specific securities or other content on this site. All content (including any links to third party sites) is provided for informational purposes only (and not for trading purposes), and is not intended to provide legal, accounting, tax, investment, financial or other advice and should not be relied upon for such advice. The views, opinions and advice of the individual authors and are not endorsed by TMX Group Limited or its affiliates. TMX Group Limited and its affiliates have not prepared, reviewed or updated the content of third parties on this site or the content of any third party sites, and assume no responsibility for your use of, or reliance on, such information.
